NASDAQ:COGT Cogent Biosciences (COGT) Stock Price, News & Analysis $7.88 +0.08 (+1.03%) As of 05:22 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Cogent Biosciences Stock (NASDAQ:COGT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cogent Biosciences alerts:Sign Up Key Stats Today's Range$7.72▼$8.2050-Day Range$7.64▼$12.0152-Week Range$4.28▼$12.61Volume1.27 million shsAverage Volume1.24 million shsMarket Capitalization$870.44 millionP/E RatioN/ADividend YieldN/APrice Target$14.83Consensus RatingModerate Buy Company OverviewCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More… Cogent Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks44th Percentile Overall ScoreCOGT MarketRank™: Cogent Biosciences scored higher than 44% of companies evaluated by MarketBeat, and ranked 684th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCogent Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Cogent Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($2.42) to ($2.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.61% of the outstanding shares of Cogent Biosciences have been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Cogent Biosciences has recently decreased by 13.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.61% of the outstanding shares of Cogent Biosciences have been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Cogent Biosciences has recently decreased by 13.30%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.28 News SentimentCogent Biosciences has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Cogent Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for COGT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.92% of the stock of Cogent Biosciences is held by insiders.Read more about Cogent Biosciences' insider trading history. Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address COGT Stock News HeadlinesCogent Biosciences (NASDAQ:COGT) Trading Down 2.5% - Here's WhyDecember 31 at 12:36 PM | americanbankingnews.comNeedham Downgrades Cogent Biosciences (COGT)December 12, 2024 | msn.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.January 3, 2025 | Weiss Ratings (Ad)Promising Market Potential for Cogent Biosciences: A Buy Rating Backed by Efficacy and Safety of BezuclasinibDecember 10, 2024 | markets.businessinsider.comCogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis PatientsDecember 9, 2024 | globenewswire.comCogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)December 8, 2024 | globenewswire.comWhy Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 4, 2024 | msn.comCogent Biosciences: Promising Clinical Developments and Strategic Milestones Warrant a Buy RecommendationNovember 14, 2024 | markets.businessinsider.comSee More Headlines COGT Stock Analysis - Frequently Asked Questions How have COGT shares performed this year? Cogent Biosciences' stock was trading at $7.80 on January 1st, 2025. Since then, COGT stock has increased by 1.0% and is now trading at $7.88. View the best growth stocks for 2025 here. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) issued its quarterly earnings data on Tuesday, November, 12th. The technology company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.07. How do I buy shares of Cogent Biosciences? Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Visa (V), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/12/2024Today1/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COGT CUSIPN/A CIK1460329 Webwww.cogint.com Phone(617) 945-5576FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$14.83 High Stock Price Target$21.00 Low Stock Price Target$10.00 Potential Upside/Downside+88.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-112.55% Return on Assets-60.44% Debt Debt-to-Equity RatioN/A Current Ratio6.44 Quick Ratio6.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book3.43Miscellaneous Outstanding Shares110,462,000Free Float103,923,000Market Cap$870.44 million OptionableOptionable Beta1.71 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:COGT) was last updated on 1/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.